Autologous Hematopoietic Stem Cell Transplant: A Potential Option for Relapsed Pediatric Acute Myeloid Leukemia With Lack of Matched Sibling Donor and Resource Challenge.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
28
12
2020
accepted:
21
04
2021
pubmed:
1
6
2021
medline:
20
4
2022
entrez:
31
5
2021
Statut:
ppublish
Résumé
Though allogeneic hematopoietic stem cell transplant (HSCT) is standard for relapsed pediatric acute myeloid leukemia, often it may not be accessible due to donor unavailability and resource limitations. We retrospectively analyzed outcomes of 26 children (mean age: 10.9±4.5 y) who underwent autologous HSCT in complete remission 2. Three-year event-free survival and overall survival were 50.1±10.7% and 63.3±9%, respectively; with 1 treatment-related death and 46% relapse rate. Notwithstanding the retrospective study design and somewhat favorable patient characteristics, the outcomes are comparable with those of other series and our own allogeneic HSCT data. Autologous HSCT is a potential alternative to allogeneic HSCT, especially in countries with poorly maintained donor registries.
Identifiants
pubmed: 34054049
doi: 10.1097/MPH.0000000000002222
pii: 00043426-202203000-00044
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e460-e462Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Abrahamsson J, Clausen N, Gustafsson G, et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol. 2007;136:229–236.
Goemans BF, Tamminga RYJ, Corbijn CM, et al. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica. 2008;93:1418–1420.
Ortega JJ, Díaz de Heredia C, Olivé T, et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica. 2003;88:290–299.
Tiedemann K, Waters KD, Tauro GP, et al. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood. 1993;82:3730–3738.
Garg A, Ganguly S, Vishnubhatla S, et al. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: a prospective, phase II study. Pediatr Blood Cancer. 2020;67:e28404.
Webb DK, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia. 1999;13:25–31.
Stahnke K, Boos J, Bender-Götze C, et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12:1534–1538.
Sakaguchi H, Muramatsu H, Hasegawa D, et al. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: a nationwide retrospective study in Japan. Pediatr Blood Cancer. 2019;66:e27459.
Woods WG. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children’s Cancer Group. Blood. 2001;97:56–62.
Pession A, Rondelli R, Paolucci P, et al. Hematopoietic stem cell transplantation in childhood: report from the Bone Marrow Transplantation Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Haematologica. 2000;85:638–646.
Anak S, Saribeyoglu ET, Bilgen H, et al. Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience. Pediatr Blood Cancer. 2005;44:654–659.
Baron F, Efficace F, Cannella L, et al. Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. Haematologica. 2020;105:e13–e16.
Godder KT, Hazlett LJ, Abhyankar SH, et al. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J Clin Oncol. 2000;18:1856–1866.
Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood. 1995;86:1636–1642.
Lazarus HM, Perez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol. 2006;132:755–769.
Arora S, Pushpam D, Tiwari A, et al. Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: lessons learnt from a tertiary care center in India. Pediatr Transplant. 2021;25:e13918.
Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–1291.